Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration.

NCT07384598 | Not Yet Recruiting

• 1 other identifier: AKI-ENOXA
• Study Type: interventional
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

Thromboprophylaxis is recommended for critically ill patients without contraindications and is usually achieved by the subcutaneous daily administration of a low dose of low molecular weight heparin (LMWH). The efficacy of this measure can be assessed by measuring the anticoagulation level obtained in the blood by dosing the anti-Xa activity. However, multiple studies have shown that anti-Xa activities in critically ill patients in the intensive care unit (ICU) are much lower, and below the desired range, than their ward counterparts. LMWH elimination depends on kidney function and reduced dosing is recommended for patients with renal failure, treated or not with renal replacement therapy (continuous veno-venous hemofiltration (CVVH)). However, some scarce data suggest that even critically ill patients with renal failure treated with reduced or even with standard doses of LMWH, also have lower anti-Xa activities (below the desired range). If confirmed, this finding may suggest that reduced or even standard dosing of LMWH for thromboprophylaxis in critically ill patients with renal failure should be replaced by another dosing regimen or another route of administration. Therefore, this study aims to better characterize the pharmacokinetic profiles of LMWH after administration of a prophylactic dose of enoxaparin daily in patients with renal failure treated or not with CVVH, and to compare them to patients with no renal failure.

Conditions

Critical Illness; Thromboprophylaxis; Intensive Care (ICU)

Keywords

thromboprophylaxis

Outcome Measures

Primary Outcomes (1)

• mean peak anti-Xa activity

  The primary endpoint will be the difference in the mean peak anti-Xa activity 4 hours after the subcutaneous administration of a prophylactic dose of enoxaparin in critically ill patients with renal failure without CVVH (N=20), in patients with renal failure with CVVH (N=20) and in a control group of patients with no renal failure (N=20).

  4 hours after the subcutaneous administration of a prophylactic dose of enoxaparin

Secondary Outcomes (2)

• Mean area under the curve (AUC) (0-24 hours) of anti-Xa activity

  0-24 hours after the subcutaneous administration of a prophylactic dose of enoxaparin

• Trough value of anti-Xa activity

  Trough value of anti-Xa activity 24 hours after the injection of a prophylactic dose of enoxaparin.

Study Arms (1)

Thromboprophylaxis arm

EXPERIMENTAL

Participating subjects will be given a prophylactic dose of enoxaparin, via the subcutaneous route, as standard of care. The enoxaparin dose will be defined according to the actual patient's body weight as follow: 40 mg daily for patients between 60 and 100 kg, 30 mg daily for patient \< 60 kg and 50 mg daily for patients \> 100 kg.

Diagnostic Test: Anti-Xa profiles after the subcutaneous administration of a prophylactic dose of enoxaparin

Interventions

Anti-Xa profiles after the subcutaneous administration of a prophylactic dose of enoxaparin DIAGNOSTIC_TEST

Monitoring of the antifactor Xa activity will be performed immediately before (H0), 4(H4), 8(H8), 12 (H12), and 24 (H24) hours after up to 3 doses of LMWH administration.

Thromboprophylaxis arm

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age \> 18 year old
• Hospitalized in the ICU.
• Equiped with an arterial line.
• Indication for thromboprophylaxis with a daily prophylactic dose of enoxaparin.
• Additionnally:
• For cohort 1: severe renal failure (KDIGO stage ≥2) without CVVH AND SOFA score ≥4.
• For cohort 2: severe renal failure (KDIGO stage ≥2) with CVVH AND sequential organ failure assessment (SOFA) score ≥4.
• For cohort 3: no renal failure (creatinine clearance \> 60 ml/min)

You may not qualify if:

• Platelet count \< 50 000/μl.
• CHILD PUGH stage C cirrhosis.
• Known coagulation disorder.
• Patient treated in the last 3 days with direct oral anticoagulants.
• Patient treated in the last 24h with LMWH before enrollment.
• High bleeding risk with contra indication for standard dose of LMWH prophylaxis, as per investigator judgment
• Indication for therapeutic anticoagulation (including CVVH with systemic heparin anticoagulation).
• Body weight \< 50 kg or \> 120 kg.
• Evidence of recovery of renal function before enrollment, based on investigator judgement.

Sponsors & Collaborators

• Clinique Saint Pierre Ottignies: lead

MeSH Terms

Conditions

Critical Illness

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Nicolas De Schryver, MD

CONTACT

+3210737251; nicolas.deschryver@cspo.be

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: January 12, 2026
• First Posted: February 3, 2026
• Study Start: February 1, 2026
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): December 31, 2027
• Last Updated: February 3, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share